V

Vimian Group AB
STO:VIMIAN

Watchlist Manager
Vimian Group AB
STO:VIMIAN
Watchlist
Price: 38.25 SEK -3.89% Market Closed
Market Cap: 19.8B SEK
Have any thoughts about
Vimian Group AB?
Write Note

Gross Margin
Vimian Group AB

46.9%
Current
58%
Average
47.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
46.9%
=
Gross Profit
165.2m
/
Revenue
352.4m

Gross Margin Across Competitors

Country SE
Market Cap 20.1B SEK
Gross Margin
47%
Country JP
Market Cap 7.1T JPY
Gross Margin
86%
Country CH
Market Cap 37.7B CHF
Gross Margin
55%
Country DK
Market Cap 177.1B DKK
Gross Margin
68%
Country US
Market Cap 16.1B USD
Gross Margin
70%
Country KR
Market Cap 10.5T KRW
Gross Margin
15%
Country CN
Market Cap 51.1B CNY
Gross Margin
72%
Country US
Market Cap 6.5B USD
Gross Margin
65%
Country CA
Market Cap 6.4B USD
Gross Margin
61%
Country UK
Market Cap 4.6B GBP
Gross Margin
56%
Country US
Market Cap 5.6B USD
Gross Margin
47%
No Stocks Found

Vimian Group AB
Glance View

Market Cap
20B SEK
Industry
Health Care

Vimian Group AB is a relatively new player making waves in the veterinary and animal health industries. Founded in Sweden, Vimian is structured as a conglomerate composed of specialized subsidiaries focused on different niche markets within veterinary services, diagnostics, and technology. This strategic structure enables the company to operate across various segments such as Veterinary Services, Specialty Pharma, MedTech, and Diagnostics, achieving a holistic approach to animal healthcare. By acquiring and partnering with innovative companies globally, Vimian capitalizes on synergies and cross-market opportunities, ensuring a competitive edge in each of its operational fields. The company’s diverse portfolio allows it to cater not only to pet owners and veterinary professionals but also to livestock industries, ensuring comprehensive coverage in the growing market of animal welfare and health. Vimian’s revenue streams are multi-faceted, generated from a blend of product sales, subscriptions, and service fees. For instance, within its Specialty Pharma segment, the company develops and sells pharmaceutical products designed to treat common and specialty conditions in animals, thus generating continuous revenue from veterinary practices worldwide. In the MedTech segment, Vimian offers cutting-edge medical devices and equipment, enhancing veterinary surgical and diagnostic capabilities, which drives sales. Meanwhile, their Diagnostics division provides innovative testing solutions that help veterinarians identify and treat animal diseases accurately, offering another lucrative revenue stream. This multi-pronged business model not only mitigates risk through diversification but also positions Vimian as a key player in meeting the rapidly evolving demands of animal health and care.

VIMIAN Intrinsic Value
45.26 SEK
Undervaluation 15%
Intrinsic Value
Price
V
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
46.9%
=
Gross Profit
165.2m
/
Revenue
352.4m
What is the Gross Margin of Vimian Group AB?

Based on Vimian Group AB's most recent financial statements, the company has Gross Margin of 46.9%.